Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Status:
COMPLETED
Trial end date:
2023-05-29
Target enrollment:
Participant gender:
Summary
A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.